There are a number of independent risk factors for stroke, most of them associated with atherosclerosis (TABLE 1 outlines those supported by level 2 evidence or higher). [4] [5] [6] [7] [8] Nonmodifiable risk factors for stroke include older age, male sex, nonwhite race, the presence of coronary heart disease or congestive heart failure, and a positive family history for stroke or transient ischemic attack (TIA). Whether diabetes mellitus is a modifiable risk factor remains open to debate. Patients with a history of TIA are at substantial risk for subsequent stroke, particularly within the first few days. 9 A cohort study of 1707 patients with TIA (68% of whom were discharged and receiving aspi-rin; 12%, ticlopidine; and 14%, warfarin) documented an 11% incidence of stroke within 90 days (half of these strokes occurred within 2 days of the TIA).
Attempts have been made to create clinical prediction rules for stroke. For example, using the Framingham data, D'Agostino and colleagues 10 developed a prediction rule for the 10-year risk of stroke. Independent predictors included age, systolic blood pressure, hypertension, diabetes mellitus, current smoking, established cardiovascular disease (any one of myocardial infarction [MI] , angina or coronary insufficiency, congestive heart failure, or intermittent claudication), atrial fibrillation (AF), and left ventricular hypertrophy on electrocardiogram (ECG). According to a patient's risk factor score, 10-year risk of stroke could vary from 1% to higher than 80%. Although this prediction rule has been independently validated, it involves a complex scoring algorithm (TABLES 2, 3, and 4), and it is not known whether its use would improve clinical decision making or health-related outcomes.
What Strategies Are Effective in the Primary Prevention of Stroke?
The impact of various primary prevention strategies is summarized in TABLE 5. However, when physicians attempt to use the results from this table in practice, they should remember that the baseline risk of stroke is variable and the resulting number needed to treat could vary by more than a thousandfold.
Treatment of Hypertension. Randomized placebo-controlled trials have established that lowering blood pressure in hypertensive individuals is effective in the primary prevention of hemorrhagic and ischemic stroke (relative risk [RR] reductions, 35%-45%). [12] [13] [14] [15] [16] Although the majority of this evidence arises from studies in patients with elevated diastolic (and systolic) blood pressure, a systematic review of 8 trials (15 963 patients) confirmed similar reductions in stroke incidence with antihypertensive therapy in elderly patients with isolated systolic hypertension (odds reduction, 30%; 95% confidence interval [CI], 18%-41%) 17 (level 1). Indeed, the benefits of antihypertensive treatment extend to patients older than 80 years (RR reduction, 34%; 95% CI, 8%-52%). 18 A systematic review of early antihypertensive trials confirmed that all of the stroke reduction anticipated (on the basis of population epidemiologic stud- [21] [22] [23] [24] [25] Although there have been no randomized trials evaluating lipid-lowering therapy for the prevention of stroke as a primary outcome, one can extrapolate from randomized trials of lipidlowering therapy because most of the patients enrolled in these studies had not had a stroke or TIA. [26] [27] [28] A systematic review by Bucher and colleagues 26 found that most lipid-lowering therapies (including resins, fibrates, and diet) did not decrease risk of stroke, although the pooled estimate from 8 trials for the relative reduction in risk of stroke with use of a statin was 24% (95% CI, 8%-38%). Warshafsky and colleagues 27 included 5 additional trials and, despite significant heterogeneity among these 13 trials, estimated an overall 30% reduction in stroke (95% CI, 14%-43%) with statin use. Since these 2 meta-analyses were undertaken, 2 large statin trials have been published with reporting of stroke outcomes. 29, 30 These studies had more events (455 strokes) than the previous 13 trials combined (404 strokes). 29, 30 We updated the Warshafsky et al meta-analysis and found statin therapy associated with a 25% reduction (95% CI, 14%-35%) in the risk of fatal and nonfatal stroke.
According to the available evidence, statin therapy is safe and is associated with a significant reduction in the risk of first stroke. However, the absolute benefits of statin therapy are greater for coronary heart disease than for stroke. Therefore, the decision to initiate lipidlowering therapy should be based on the presence or absence of other cardiovascular risk factors as well as the actual lipid levels, as suggested by the evidencebased guidelines of the National Cholesterol Education Program. 31 Without clinically manifest atherosclerosis or diabetes, the recommended level for LDL cholesterol is less than 130 mg/dL (3.36 mmol/L). 31 In individuals with overt atherosclerosis or diabetes mellitus, the recommended level for LDL cholesterol is less than 100 mg/dL (2.59 mmol/L).
Antithrombotic Therapy for AF. Patients with AF have a mortality rate double that of age-and sex-matched controls without AF, largely because of an increased risk of stroke and systemic emboli. 32 Indeed, the risk of stroke in the average patient with nonrheumatic AF is approximately 5% a year, 33 and patients with valvular AF have an even higher risk (17-fold increase above that of age-and sexmatched controls). However, the risk of stroke in an individual patient varies widely, depending on the presence of associated risk factors (TABLE 6). 34 Although it has long been accepted that warfarin therapy is efficacious in preventing strokes in patients with rheumatic AF, 35 randomized trials published in the past decade have defined the benefits of antithrombotic therapy (warfarin or aspirin) in patients with nonrheumatic AF. However, 2 points arising from the accumulated evidence deserve emphasis. First, antithrombotic therapy effectively prevents strokes of all severities, and the strokes that occur in patients receiving warfarin or aspirin are not more severe than those occurring in placebo-treated patients. Second, although retrospective studies suggested that paroxysmal AF was associated with a lower stroke risk than chronic AF, analyses of the recent trial data after controlling for confounders reveals that the stroke risks (and benefits of antithrombotic therapy) were similar for patients with paroxysmal or chronic AF. 36, 37 Antithrombotic therapy is not without risks (particularly of bleeding) or inconvenience. Although the trials demonstrated that the risk of major extracranial hemorrhage was minimally increased in warfarin-treated patients (by 0.3% per year), 38 between 53% and 93% of screened patients were excluded from these trials (in many cases because of perceived bleeding risks), and trial participants are likely to be more compliant and more closely followed up than other patients. Although the low hemorrhage rate observed in the trials is unlikely to be duplicated in actual practice, the risk factors for hemorrhage with warfarin therapy are now relatively well defined, 39, 40 and it should be possible to target therapy to individuals with low bleeding risk. Indeed, a prospective cohort study conducted in elderly patients with AF confirms that the excess bleeding risk with warfarin can be similar to the low rates achieved in the randomized trials. 41 In summary, although there is strong trial evidence that warfarin is the most efficacious agent in preventing stroke, individual AF patients have different stroke risks and thus differ in their potential to *Calculated by assuming that the annual risk of stroke is 0.03% (except where otherwise indicated) and using the best estimates of RR reduction from the literature, assuming constant RR reduction over time. 11 Note that the baseline risk is variable (ranging from Ͻ1%-80%), and therefore the number needed to treat could vary by more than a thousandfold, depending on this risk. †Calculated by assuming that the risk of stroke is 0.01% over 2 years. ‡Calculated by assuming that the annual risk of recurrent stroke is 7% (except where otherwise indicated) and using the best estimates of RR reduction from the literature, assuming constant RR reduction over time.
11 §Numbers in parentheses are the percentage of all recurrent strokes avoided a year, assuming that all eligible patients receive the intervention. The percentage was calculated by factoring the absolute risk reduction from the intervention by the prevalence of the underlying risk factor in the population that has already experienced a stroke or transient ischemic attack. Calculated by assuming that the annual risk of recurrent stroke in a patient with nonrheumatic atrial fibrillation is 12%. ¶Calculated by assuming that the annual risk of recurrent stroke in a patient with moderate to severe carotid stenosis is 8.8%. benefit (Table 6 ). The decision to use warfarin, aspirin, or nothing in a patient with AF requires consideration of his or her individual risk and values. Antithrombotic Therapy After MI. The risk of ischemic stroke is increased after an MI, particularly in the first month and in patients with left ventricular systolic dysfunction. 42, 43 A metaanalysis of more than 140 trials (more than 72000 patients) revealed that aspirin reduced the risk of nonfatal stroke (odds reduction, 31%; 95% CI, 24%-37%) in patients who had experienced an MI or other vascular event.
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Treatment of Diabetes Mellitus. Diabetic patients are at increased risk for all forms of ischemic stroke and are more likely to have hypertension and hyperlipidemia.
4-6 We did not identify any level 1 or 2 evidence to support the tenet that better glucose control is associated with a reduced risk of stroke. None of the 3 major randomized studies that have tested the glucose control hypothesis demonstrated significant reductions in the risk of ischemic stroke or any other macrovascular outcomes. [45] [46] [47] Lack of statistical power cannot be cited as a reason for the lack of benefit observed in the studies involving patients with type 2 diabetes. For example, in the United Kingdom Prospective Diabetes Study (UKPDS), there were far more macrovascular events than microvascular (eg, almost twice as many MIs as all microvascular events combined), yet the UK-PDS was able to demonstrate a 25% relative reduction (95% CI, 7%-40%) in microvascular complications with more intensive glucose control. 47 Nested within the UKPDS was a smaller randomized trial of tight (Ͻ150/85 mm Hg) vs usual (Ͻ180/105 mm Hg) blood pressure control. This substudy demonstrated a 44% relative reduction (95% CI, 37%-90%) in stroke with tighter blood pressure control. 48 This stroke benefit was independent of the level of glycemic control and the antihypertensive regimen used.
Tobacco Cessation. We were unable to identify any high-quality randomized trials evaluating the effects of smoking cessation on risk of stroke. However, given the results from observational data (Table 5) , physicians should discuss smoking cessation interventions with their patients 49 (level 2). A cohort study 50 found that the risk of stroke decreased after cessation of smoking and that the elevated risk in smokers disappeared within 5 years. This decline in risk was independent of a patient's age, highlighting that it is never too late to quit. Systematic reviews have shown that 1-time advice from physicians during routine consultation results in 2% of smokers quitting for at least 1 year [51] [52] [53] [54] (level 1). Similarly, nicotine replacement, some antidepressants, and advice from psychologists and nurses can enhance cessation (level 1). 55, 56 Antiplatelet Therapy. The effectiveness of aspirin in the primary prevention of stroke is controversial because 4 observational studies demonstrated a consistent association between regular use of aspirin and increased risk of stroke. 57 However, the aspirin use in these studies was self-selected, and the studies may have been confounded by the uneven distribution of risk factors. In a meta-analysis, Hart and colleagues 57 identified 5 randomized trials that evaluated aspirin vs placebo for primary prevention of stroke (level 1). We identified another 3 eligible studies and updated their data. [58] [59] [60] These 8 trials included 59977 patients randomized to various dosages of aspirin (75-990 mg/d). Aspirin reduced the frequency of all cardiovascular events (RR, 0.89; 95% CI, 0.82-0.96) but largely because of substantial reductions in MI risk. In fact, stroke risk was marginally increased with aspirin therapy (RR, 1.07; 95% CI, 0.95-1.22), particularly hemorrhagic strokes. The risk of major bleeding was also increased with aspirin therapy (RR, 1.53; 95% CI, 1.15-2.04). Thus, although the use of aspirin may be beneficial in the primary prevention of MI, it is not efficacious for the primary prevention of stroke.
ACE Inhibitors. Data from trials comparing different antihypertensive agents are difficult to interpret because of methodologic flaws, 20 but it is unlikely that ACE inhibitors confer more stroke prevention than other classes of antihypertensives (indeed, the data suggest a possible trend in the other direction). 19 However, a systematic review of 4 randomized placebo-controlled trials demonstrated that for patients with established coronary heart disease, ACE inhibitors were associated with a 30% reduction in the risk of stroke (95% CI, 15%-43%). 19 Ninety-four percent of the stroke outcomes in this meta-analysis were contributed by 1 trial, the Heart Outcomes Prevention Evaluation (HOPE) Study. 61 HOPE was a randomized trial comparing ramipril with placebo in 9297 normotensive (mean blood pressure, 139/79 mm Hg) patients at "high risk of cardiovascular events." 61 Although widely cited as a study of primary prevention, 88% of patients had established cardiovascular disease at study entry. Over 4 years, the reduction in the risk of stroke was 32% (95% CI, 16%-44%). 61 The extent to which these benefits were related to blood pressure lowering rather than a ramiprilspecific effect on atherogenesis is unclear 62 and awaits clarification from ongoing trials. [63] [64] [65] We believe that the treatment of hypertension to appropriate target blood pressure is more important than the debate about which agent to use, since there is no clear evidence that any antihypertensive class is superior. 66 However, in patients whose blood pressure is well controlled but who remain at high risk for an event, the addition of an ACE inhibitor such as ramipril should be considered.
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Carotid Endarterectomy for Asymptomatic Stenosis. For people with asymptomatic carotid disease, the optimal treatment strategy is unclear. A systematic review of 5 randomized trials (more than 2400 patients) comparing carotid endarterectomy to medical therapy in patients with asymptomatic carotid stenosis higher than 50% found that the risk of stroke or death was increased in the immediate perioperative period (RR increase, 423%; 95% CI, 127%-1107%) 67 (level 1). However, the risk of the combined end point of stroke or death was reduced throughout the subsequent 3 years (RR reduction, 30%; STROKE PREVENTION 95% CI, 9%-45%), which suggests that more evidence is needed to identify subgroups of patients who are at lower risk of surgical complications and would derive more benefit from surgery.
What Strategies Are Effective in the Secondary Prevention of Stroke?
Approximately 7% of all patients with a history of TIA or stroke will have a recurrent event each year. 68 Strategies targeted to the secondary prevention of stroke are likely to be more costeffective than primary prevention strategies, since the RR reductions are often constant across various baseline risks (at least for medical interventions), 11 meaning that the absolute risk reductions are substantially higher (and the numbers needed to treat are thus substantially lower) in patients at higher risk (ie, those who have already experienced an event). The impact of various secondary prevention maneuvers is summarized in Table 5 .
Treatment of Hypertension. There is a continuous, strong, and graded relationship between blood pressure level and the subsequent occurrence of stroke in patients who already have cerebrovascular disease 69 ; a systematic review of the trial literature confirms that this risk can be reduced by antihypertensive therapy (RR reduction, 28%; 95% CI, 15%-39%) 70 (level 1). The recently published Perindopril PROtection AGainst REcurrent Stroke Study (PROGRESS) 71 further reinforces this. Although intended to test the benefit of ACE inhibitor-based blood pressure lowering on the secondary prevention of stroke, because of its complex design it may be interpreted as a test of 2 targets for blood pressure control. There was an overall 9/4 mm Hg difference in blood pressure between the perindoprilbased and placebo arms, associated with a 28% relative reduction (95% CI, 17%-38%) in the risk of stroke. However, physicians had the prerandomization opportunity to state their intent with respect to treatment intensity, and if they intended to offer more intensive treatment, their patients were randomized to combination therapy with perindopril and indapamide or double placebo. Compared with placebo, perindopril monotherapy achieved a 5/3 mm Hg difference in blood pressure and no benefit in terms of stroke (5% risk reduction; 95% CI, -19% to 23%), while perindopril/indapamide combination therapy achieved a 12/5 mm Hg difference in blood pressure and a 43% reduction (95% CI, 30%-54%) in the RR of stroke. Thus, the benefits of antihypertensive therapy appear to depend more on the blood pressure targets achieved than the agents used. However, given the paucity of controlled clinical trials, it remains unclear how acutely and by how much blood pressure should be lowered after a stroke. Data from observational studies support the familiar adage that all but the highest blood pressures should be left to settle spontaneously in the acute setting.
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Treatment of Hyperlipidemia. There are no published randomized trials of lipid-lowering therapy for the secondary prevention of stroke, although 2 large-scale studies are under way. 73, 74 As mentioned in our discussion of primary prevention, statins may reduce the risk of stroke by 25%. As do the National Cholesterol Education Program guidelines, we consider that patients who have experienced an ischemic stroke or TIA have a coronary heart disease risk equivalent, 31 and until randomized trial data show otherwise, we believe that stroke patients with hyperlipidemia will benefit from statin therapy and that their target for LDL cholesterol should be 100 mg/dL (2.59 mmol/L).
Antithrombotic Therapy for AF. Four randomized trials provide information on treatment strategies for the secondary prevention of stroke in survivors of TIA or stroke. [75] [76] [77] [78] The data from these trials confirm a substantial benefit with adjusted-dose warfarin (RR reduction, 68% vs placebo; RR reduction, 71% vs lowdose warfarin plus placebo) and a smaller but still significant benefit with aspirin (RR reduction, 17%-29% vs placebo). Although these relative benefits are similar to those seen in the AF primary prevention trials, the absolute benefit is higher in patients with prior TIA or stroke, given their markedly higher stroke risk at baseline (Table 6 ).
The timing of warfarin initiation after stroke is unclear. It is generally recommended that anticoagulants not be prescribed for the first few days after an ischemic stroke, especially if the infarct is large, because of concerns about the potential for hemorrhagic transformation. 79 However, we could not identify any level 1 or 2 evidence evaluating the timing of anticoagulant administration after stroke.
Antiplatelet Therapy. A recent systematic review of 287 randomized trials in high-risk patients found that antiplatelet agents significantly decreased the risk of stroke (odds reduction, 31%; SE, 5%). 44 The Antiplatelet Trialists' Collaboration 44 did not find a significant difference between high (500-1500 mg/d) and medium (75-325 mg/d) doses of aspirin, but the number of vascular events in these studies was small. A second systematic review noted similar results: aspirin decreased the risk of stroke in patients with previous TIA or stroke, and no dose-response relationship was observed 80 (level 1). Thus, the protective effect of aspirin appears to be uniform across doses of 50 to 1500 mg/d, while larger doses increase the risk of gastrointestinal bleeding 81 (level 1). The lowest effective dose of aspirin has not yet been identified.
A systematic review of 4 trials (Ͼ22000 patients) found that thienopyridines (clopidrogel and ticlopidine) are modestly more effective than aspirin at decreasing the risk of the combined end point of stroke, MI, or vascular death in patients at high risk of a vascular event (RR reduction, 8%; 95% CI, 2%-14%) 82 (level 1). In patients with a history of stroke, thienopyridines decreased the RR of stroke by 13% (95% CI, 3%-22%) above that of aspirin. 82 (level 1). Use of thienopyridines decreased the risk of gastrointestinal bleeds but increased the risk of rash and diarrhea, particularly with use of ticlopidine. Similarly, patients allocated to ticlopidine were at increased risk of neutropenia (odds ratio, 2.7; 95% CI, 1.5-4.8). There are insufficient data to determine which patient subgroups would benefit most from these agents instead of aspirin.
In their review, the Antiplatelet Trialists' Collaboration did not find that adding dipyridamole to aspirin resulted in significant benefit over the use of aspirin alone, 44 but they noted that a single randomized trial found that the addition of extended-release dipyridamole to aspirin decreased the risk of death significantly. 83 The ESPRIT trial 84 (in which patients with prior stroke or TIA are randomized to warfarin, dipyridamole and aspirin, or aspirin alone) should provide additional guidance on this topic when it is completed.
Carotid Endarterectomy. A systematic review of 3 randomized trials found that carotid endarterectomy decreased the risk of stroke or death in patients with symptomatic carotid disease and severe carotid artery stenosis, defined as 70% to 99% by North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (RR reduction, 48%; 95% CI, 27%-73%, over approximately 2.5 years) 85 (level 1). Similarly, patients with symptomatic moderate carotid artery stenosis, defined as 50% to 69% by NASCET criteria, had a decreased risk of stroke or death with surgery, although the benefits were more marginal (RR reduction, 27%; 95% CI, 15%-44%, over 5 years). However, patients with lesser degrees of stenosis (Ͻ50% by NASCET criteria) were harmed by surgery (RR increase, 20%; 95% CI, 0%-44%).
The results of these studies are applicable only if the surgical complication rate is less than 6%. Indeed, the benefits from carotid endarterectomy would be reduced by 20% for each 2% increase in perioperative stroke and death rates. 86 Moreover, surgical teams whose complication rates and operative volumes would have rendered them ineligible for the NASCET trial perform most carotid endarterectomies. 87 Not all patients with operable lesions benefit from surgery. Rothwell and colleagues 87 performed a systematic review of the carotid endarterectomy literature and identified clinical and angiographic characteristics that increase a person's risk of perioperative stroke or death. Five clinical characteristics were associated with an increased risk of perioperative stroke or death: surgery for stroke (vs surgery for amaurosis fugax), female sex, older than 75 years, systolic blood pressure higher than 180 mm Hg, and history of peripheral vascular disease. The presence of contralateral internal carotid artery occlusion and stenoses of the intracranial portion of the ipsilateral internal carotid artery and of the ipsilateral external carotid artery as seen on angiography also increased the risk of stroke or death. However, this review included retrospective studies, and its results may be an overestimate. Moreover, this prediction rule needs to be validated in an independent population before it can be recommended for clinical use.
CONCLUSIONS
Stroke is a major public health concern, and efforts should be focused on its prevention. We have provided a brief overview of some of the recent developments in stroke prevention in an attempt to bridge the gap between research and practice and to achieve knowledge translation. 
